Study identifies genetic basis of rifamycin resistance in Mycobacterium abscessus and reveals potential combination therapy strategies
Researchers used transposon insertion sequencing to identify genes responsible for intrinsic rifamycin resistance in Mycobacterium abscessus, a pathogen with limited treatment options. The study found that resistance mechanisms in M. abscessus differ from those in tuberculosis-causing M. tuberculosis, and identified MAB_2807 as a major efflux-based resistance contributor. The findings suggest that combining rifamycins with specific beta-lactam antibiotics may overcome resistance and improve treatment for this difficult-to-treat infection.
Researchers conducted a genome-wide screen using transposon insertion sequencing to identify genes conferring intrinsic rifamycin resistance in Mycobacterium abscessus, a bacterium resistant to many antibiotics including rifampicin, a key tuberculosis drug. The study confirmed previously known resistance genes (arr, helR, MAB_2807) and discovered additional genetic determinants, particularly those involved in cell envelope processes. Notably, the resistance mechanisms in M. abscessus proved distinct from those in M. tuberculosis despite both bacteria's rifamycin resistance. The researchers validated their findings by characterizing targeted mutants and found that disrupting MAB_2807 increased intracellular rifampicin accumulation. Guided by these genetic insights, the team evaluated combination therapies and discovered selective synergistic interactions between rifamycins and specific beta-lactam antibiotics. The study also revealed that rifampicin exposure alters cell envelope structure and disrupts metabolic homeostasis, identifying vulnerable cellular processes that could inform rational drug combination strategies.
What's missing
The study does not specify the clinical implications or timeline for translating these findings into new treatment protocols for M. abscessus infections. Additionally, the specific beta-lactam antibiotics showing synergy are not detailed in the abstract, and the study does not address whether these combinations have been tested in animal models or clinical settings.
What different sources said
- bioRxivCenter
Transposon insertion sequencing identifies genetic determinants of intrinsic rifamycin resistance in Mycobacterium abscessus
Related
Study Shows Statins Reduce Coenzyme Q in Brain Cells, Impairing Mitochondrial Function
A laboratory study found that statin drugs decrease coenzyme Q levels in astrocytes (brain support cells) by 30-40%, reducing their mitochondrial energy production and increasing oxidative stress. Astrocytes are critical for maintaining brain health and protecting neurons from damage. The findings suggest CoQ10 supplementation may help counteract these effects, though human clinical evidence remains limited.
Study reveals zebrafish larvae exhibit slowly fluctuating directional swim biases driven by internal dynamics
Researchers found that 5-day-old zebrafish larvae display changing directional swim preferences over many hours even in stable environments, contrary to classical models assuming constant individual biases. Computational analysis suggests these fluctuations arise from a non-stationary Markovian process with two independent internal input streams modulating swim direction repetition. The findings suggest animals possess intrinsic mechanisms for generating behavioral variability independent of external stimuli, with implications for understanding how internal states shape adaptive behavior.
Two Small Molecules Show Promise as Broad-Spectrum Coronavirus Inhibitors in Laboratory Study
Researchers found that sennoside A and ceftazidime, two small molecules, can inhibit RNA binding in the nucleocapsid proteins of SARS-CoV-2, SARS-CoV, and MERS-CoV in laboratory experiments. The nucleocapsid protein is highly conserved across coronaviruses and essential for viral replication, making it a potential drug target. The findings suggest these compounds could form the basis for pan-coronavirus antiviral therapies, though further development and clinical testing would be needed.